MedTrace Logo

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

NCT04876456 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-15

No results posted yet for this study

Summary

The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.

Conditions

  • Germ Cell Tumor
  • Seminoma
  • Non-seminomatous Germ Cell Tumor
  • Ovarian Germ Cell Tumor

Interventions

DRUG

Cabozantinib

Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • JDS Foundation Testis Cancer Clinical Trials Support Fund

    collaborator UNKNOWN

  • Jennifer King

    lead OTHER

Principal Investigators

  • Jennifer King, MD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04876456 on ClinicalTrials.gov